LRRK2 is associated with an increased risk of both autosomal dominant Parkinson’s disease and Crohn’s disease. In the SAD cohort, a single oral dose of at least 60mg of ARV-102, alongside further once ...

Study participants were randomly assigned to receive BIIB080 10mg once every 4 weeks (Q4W), 30mg Q4W, 60mg Q4W, 115mg Q12W or placebo. In the long-term extension portion of the study, participants ...

The double-blind, placebo-controlled study included 298 patients (pNET cohort: n=99; epNET cohort: n=199) who were randomly assigned 2:1 to receive cabozantinib 60mg orally once daily or placebo until ...